ATE373657T1 - Androgen-rezeptor-modulatoren und verwendungsverfahren dafür - Google Patents

Androgen-rezeptor-modulatoren und verwendungsverfahren dafür

Info

Publication number
ATE373657T1
ATE373657T1 AT02778604T AT02778604T ATE373657T1 AT E373657 T1 ATE373657 T1 AT E373657T1 AT 02778604 T AT02778604 T AT 02778604T AT 02778604 T AT02778604 T AT 02778604T AT E373657 T1 ATE373657 T1 AT E373657T1
Authority
AT
Austria
Prior art keywords
bone
compounds
useful
patient
androgen
Prior art date
Application number
AT02778604T
Other languages
English (en)
Inventor
Paul Coleman
Lou Anne Neilson
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE373657T1 publication Critical patent/ATE373657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02778604T 2001-10-19 2002-10-15 Androgen-rezeptor-modulatoren und verwendungsverfahren dafür ATE373657T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33486601P 2001-10-19 2001-10-19

Publications (1)

Publication Number Publication Date
ATE373657T1 true ATE373657T1 (de) 2007-10-15

Family

ID=23309205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02778604T ATE373657T1 (de) 2001-10-19 2002-10-15 Androgen-rezeptor-modulatoren und verwendungsverfahren dafür

Country Status (9)

Country Link
US (1) US7196076B2 (de)
EP (1) EP1439841B1 (de)
JP (1) JP2005509629A (de)
AT (1) ATE373657T1 (de)
AU (1) AU2002340256B2 (de)
CA (1) CA2463311A1 (de)
DE (1) DE60222577T2 (de)
ES (1) ES2291507T3 (de)
WO (1) WO2003034987A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
IT1397000B1 (it) * 2009-11-12 2012-12-20 Antropoli Uso di un preparato basato sulla nifedipina per il trattamento del vaginismo
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
CN103945868B (zh) 2011-05-13 2016-10-26 国立大学法人东京医科齿科大学 骨生成促进剂
WO2013078244A1 (en) 2011-11-21 2013-05-30 Promega Corporation Carboxy x rhodamine analogs
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP3094323A4 (de) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
US20190375732A1 (en) 2018-05-14 2019-12-12 David Hung Anti-cancer nuclear hormone receptor-targeting compounds
EP3956309A4 (de) 2019-04-19 2023-06-07 Ligand Pharmaceuticals Inc. Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN111170943B (zh) * 2020-01-22 2021-03-26 浙江大学 苯并[f]环戊烷并[c]喹啉衍生物及其应用
EP4313991A1 (de) 2021-03-23 2024-02-07 Nuvation Bio Inc. Gegen krebs gerichtete kernhormonrezeptorverbindungen
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738974A (en) * 1994-09-05 1998-04-14 Mitsubishi Chemical Corporation Photopolymerizable composition and photosensitive lithographic printing plate
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
DE69709752T2 (de) * 1996-06-27 2002-07-18 Ligand Pharmaceuticals, Inc. Androgen rezeptor modulator verbindungen und verfahren
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6083956A (en) * 1998-11-20 2000-07-04 Pfizer Inc. Optically pure androgen mediator
US6667313B1 (en) * 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods

Also Published As

Publication number Publication date
DE60222577T2 (de) 2008-06-19
EP1439841A2 (de) 2004-07-28
JP2005509629A (ja) 2005-04-14
EP1439841B1 (de) 2007-09-19
EP1439841A4 (de) 2005-11-09
AU2002340256B2 (en) 2007-04-05
ES2291507T3 (es) 2008-03-01
CA2463311A1 (en) 2003-05-01
DE60222577D1 (de) 2007-10-31
US20040198717A1 (en) 2004-10-07
US7196076B2 (en) 2007-03-27
WO2003034987A3 (en) 2003-09-12
WO2003034987A2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
WO2003026568A3 (en) Androstanes as androgen receptor modulators
ATE373657T1 (de) Androgen-rezeptor-modulatoren und verwendungsverfahren dafür
WO2003092588A3 (en) 4-azasteroid derivatives as androgen receptor modulators
BR0308355A (pt) Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto
WO2004100874A3 (en) Androgen receptor modulators and methods of use thereof
EA201201221A1 (ru) Фармацевтическая композиция для контрацепции и заместительной гормональной терапии
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
GB0108591D0 (en) Therapeutic agents
BG107697A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
MY141476A (en) 5ht2c receptor modulators
DE69927050D1 (de) Biphenylverbindungen und biphenyl-analoge als intergrin-antagonisten
MY146809A (en) Treatment and prevention of osteoporosis
IL172419A0 (en) Piperazine derivatives and methods of use
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
EP1420827B8 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение
WO2005005606A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
AU5548801A (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
WO2014144584A3 (en) Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2003059293A3 (en) 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
DE69920259D1 (de) Ionenkanal modulatoren
WO2005005380A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2005044988A3 (en) 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
ATE296814T1 (de) Ionenkanal modulierende mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties